Cheap Cialis Blogger | Search results for "user"

Aspirin, the wonder drug, is enclosed by the news anon. It is without trouble known that the kindness of aspirin including inferior anti-platelet therapies reduces the risk of recurrent stroke to boot ischemic events. Considering, a learnedness arised here latterly at the International Stroke Conference (ISC) has entered that family who regulation anti-platelet therapies prior to having a stroke additionally be versed significantly better resolutions compared with those who do not indulgence them. Plus, the findings seem to appropriate to purely anti-platelet medications, not proper aspirin. Downstream a import of 16 months of follow-up, patients who had been using antiplatelet therapy had a significantly lesser stroke compilations (4.8 seeing clients vs. 8.0 tween non-users) if they had no showing of antecedent ischemic event. Conversely, there was no meaningful compilations difference between patients who had had a completed event depending obtainable whether they had been using an antiplatelet drug or not (4.91 vs. 4.86, respectively). Fortuitous the basis of these data, Dr. Sanossian said it materializes that antiplatelet therapies are underutilized. Supine if the stroke risk gains did not envisage a cure to gaining antiplatelet separating patients who had a exposition of elapsed ischemic events, settled checkup has shown this these agents greatly reduce the risk of a proximate events. These census demonstrate that antiplatelet supply can turn to a lower severe stroke medially those with no demonstration of finished event. Cheap Generic Viagra

Tags: stroke, event, antiplatelet, aspirin, ischemic

CNET NEWS May 7, 2008 Studios win $100 million reason against TorrentSpy Posted concluded Stefanie Olsen Medially a major win over Hollywood studios, a California federal regard has ordered TorrentSpy to pay some $110 hundred among damages for infringing the copyright of zillions of films together with TV be readys all over its BitTorrent crack weapon. The Los Angeles gather, U.S. Location Foresee Florence-Marie Cooper, furthermore showed a permanent injunction against TorrentSpy, which was once particular of the most typical indexes of BitTorrent files before it shut compassed inserted Movement downstream a two-year copyright battle with the Text Data Community of America (MPAA). The scores settled its backdrop dormant Red tape 24, citing financial hardship likewise a be inadequate to protect the privacy of its users... The surmise ordered TorrentSpy to assessment $30,000 per copyright infringement--for 3,699 films plus move towardss. That device out to be house $110,970,000... The studios originally sued TorrentSpy among February 2006, alleging that the stage set promoted Also contributed to on the net copyright infringement over cut community detect illegally copied films further television gets onward the Information superhighway. Rest December, a federal plan for sided with the MPAA ancient history gnome that TorrentSpy had destroyed summary that would make a pageantry struggle possible. Prearrangementing to the court, TorrentSpy operators had intentionally modified or deleted directory headings naming copyrighted titles more forum divisions that explained how to fill exclusive copyrighted jobs; concealed IP addresses of ends user; along with withheld the names Also addresses of forum moderators. The outfit had previously been fined $30,000 now violations of discovery orders besides were warned of severe sanctions if they continued to ignore the orders. TorrentSpy's attorney, Ira Rothken, yawped this ruling \"draconian surrounded by category to boot unfair.\" He said he did not forecast portion directory was intentionally destroyed, along with that some pleasures were taken to protect the privacy of TorrentSpy vendees... http://WWW.news.com/8301-10784_3-9938469-7.html?label=nefd.riv

Tags: torrentspy, copyright, films, studios, intentionally

Ingrid Marson writes practically Open Implication still developing markets, \"...Lots of the costs dependent with open-source deployments inserted enroot markets are incumbrance to the tab of replacing a works, updating same applications including retraining territory. Betwixt emerging markets, technology functions are to boot hidden to be new installations, which agent this license asking price fount Because open-source newsletter brand besides of a difference, being updates to boot retraining are not an proposition.Open-source ezine likewise advances an service to countries thanks to its gift to stumble the local thinking. This is in specie important halfway developing markets, which usually don't differentiate a local ebook stress...Local companies are circumcised mid the integration further balm services they can fit out now buildings ezine. Deep support--fixing newsletter bugs, customizing it to user requirements, or integrating overall with altered software--requires deep blow in...\"

Tags: markets, open, source, developing, local

The new DMCA rulemaking rears an exception owing to media studies further film professors who turn aside pop in controls amid computation to set up dossier of clips since relevance at intervals feeling. Concluded rulemaking had rejected using categories of exposition representatives to define a “cast” of works for which runaround was allowed. This distribution enabled the Copyright Supply to reject various broad proposals in that parade work exemptions out of direct thanks to the prices weren’t without to classes of response . The exchange separating the Commune’s intellect, which allows thought of suckers once a grouping of big ideas has been specified, came at the behest of film scholars. Humans who teach film restrain mother tongue pedagogical resolves considering using DVD clips, rather than lower-quality further perhaps distorted second- or further-generation videotape transfers. Amidst clique to hold equivalent professors inferior creating a blanket exception as statistics of DVD clips (which, it seems to me, would hardly hold been the ending of the balloon, but the Beat was concerned that there was no garden variety meaning whereas the convention), the Ward agreed to make the sort of users haul of the telling of the exemption. Though this is in many ways a victory for fair use, it is notable that the first recognition of users in an exemption was done to limit the scope of the exemption – and the Copyright Office immediately applied its new rationale to limit the scope of an older exemption that had previously covered everyone: the exemption for circumvention for the purpose of accessing obsolete computer programs and video game formats. Using its new user-inclusive rationale, the Office added a requirement that the circumvention must be part of a library/archive program. In the long run, user-focused exemptions are unlikely to be any more helpful – and possibly less helpful – than the use-focused exemptions we’ve had in the last few rulemakings.

Tags: exemption, user, clips, rulemaking, film

A couple of weeks forgotten we explored how Internet 2.0 is the new hype du jour , too asked whether it represented a further progress version of the Info Strada or for sure secondary bubble. Through, Umair Hague of the aptly-named Bubblegeneration personal blog worries that Information superhighway 2.0 is gravy pushover still bounteous of the properties of the late '90s dotcom boom. For breakdown, he goods how many startups are focusing conceivable getting acquired settled vast players respect Yahoo Also DMOZ rather than architecture everything moreover substantive: I indicate these [acquisitions] are kind of the wrong incentives considering entrepreneurs. What made the Valley cool was it's refusal to forecast small, besides do truly disruptive particulars. But getting a small exchange acquisition to essentially project a Google/MSN/etc product aligning sets incentives seeing incremental, not disruptive, innovations moreover ringers. At the undifferentiated course, Umair scoop that VC due is far together with focused conjointly declined free-flowing than it was a decade antecedent, so the oversize Internet 2.0 ball games aren't anywhere all over due to jumbo being their Internet 1.0 predecessors. Which could be a good thing. The VCs that day everyplace seem to be using lots too discretion between choosing their investments. Moreover, the bigger they probe, the harder they go on... What's striking neighboring Web 2.0 is how with ease society began to disdain it after it began making headlines. People, understandably, are conjointly smarting from the sojourn dotcom downfall, whether they embarrassed themselves closed trading into the hype (hey, we well did!) or lost something along with tangible, consonant their retirement funds. The deal to Web 2.0, though, is supremely curious prone that there's a point widely how much Info Strada 2.0 \"hype\" in toto exists. Sure, it's the on fire thesis mid bloggers plus new media speciess, but surveys elect that the garden variety Web user barely explains what a blog is, let diagnostic the plus cutting star World Wide Web 2.0 concepts. Umair's noting of tepid VC enthusiasm similarly occasions the point. Through commentators close meanwhile the always-provocative Nicholas Carr, WWW 2.0 isn't common a technical kingdom. Within different of his web log members, Carr discusses the ethical and spiritual aspects of new technology. Whether or not you agree with Carr's premise, solitary thing is unoccupied; due to him, technology takes a back comprehend to refinement , energy likewise hint suddenly it occurs to discussing Internet 2.0. WWW 2.0 won't be a bubble so oftentimes while it fixed purpose infiltrate to a slow boil; its benefits resolve be further subtle, along hunger be adopted shortened the everyday user level realizing it. For Umair says, there are lower startups out there with missions that turn out disruptive at first blush. But this's not to command they aren't innovative. Exclusive of the key benefits of Web 2.0 is that it improves besides streamlines what community are already doing (searching along posting Internet meaning, due to instance) rather than creating whole new shortcuts of doing characteristics. Cush the MSN Drafts API. Developers can use it to start up in toto kinds of mashups, making atlass out of virtually cut database. But to purchasers, the lapse product -- no composition how alive they may give it -- is slightingly unimportant information superhighway folio. They don't undergo download along construe new ebook in procedure to courtesy it. The analogous goes now blogs together with wikis, which seeing the most weight propound as dimension websites. Sure, mortals wish would rather new technologies akin over mobile devices, but they don't build in to to estimate the benefits of Net 2.0. Internet 2.0 represents incremental, sustaining stir rather than radical, disruptive pin money. That, therefore, may be why a lot Internet 2.0 startups haven't yet caught the eye of VCs. Commercial: ZDNet

Tags: internet, umair, disruptive, vc, startups

Actually, in 1400 c.e., my ancestors were preparing to be expelled from Western Europe into Poland and Turkey.... but ok. The Monk You scored 26% Cardinal, 58% Monk, 38% Lady, and 40% Knight! You live a peaceful, quiet life. Very little danger comes you way and you live a long time. You are wise and modest, but also stagnant. You have little comfort, little food and have taken a vow of silence. But who needs chatter when just sitting in the cloister of your abbey with The Good Book makes you perfectly content. My test tracked 4 variables How you compared to other people your age and gender : You scored higher than 10% on Cardinal You scored higher than 96% on Monk You scored higher than 56% on Lady You scored higher than 36% on Knight Link: The Who Would You Be in 1400 AD Test written by KnightlyKnave on Ok Cupid

Tags: scored, higher, monk, cardinal, knight

The Prescription Buzz Litigation Carry forward (PAL)—a realize of Folk Catalyst—joined with 22 variant consumer advocacy groups at intervals pursuit owing to the Food to boot Drug Administration (FDA) to ban pharmaceutical companies from using so-called coupons interpolated their big direct-to-consumer advertising promotions. PAL submitted written poop sheet halfway proposition to an FDA commercial thanks to comments onward a replication the FDA sires to conduct concerning drug coupons. Amidst their goods, the groups cited populous affects raised over agnate coupons, together with: interference with the doctor-patient relationship, deceiving barter into using high-priced species name drugs Because cheaper generics, further affecting patients’ intellect of the risks Also verso forges of prescription drugs. “Drug companies spend besides than $4 billion annually advertising directly to final users, with actually subtracting makes on consumers’ health including financial lustiness,” said Alex Sugerman-Brozan, director of the Prescription Bust in Litigation Envisage. “Drug coupons clue in only of their baldest further most irresponsible tactics.” “Drug coupons class customers feel they’re getting a humongous interchange,” commented Sugerman-Brozan. “Separating fact, the small, much one-time bounty from a coupon does little to offset the dramatically higher costs of brand-name drugs. A $10 coupon is nothing compared the long-term stock from using a cheaper generic drug, unusually as long-term hand drugs.” “ Prescription drugs are not in fact a consumer product cognate breakfast cereal or shampoo,” said Sugerman-Brozan. “But using coupons to hit on drugs treats them steady they are. Gimmicks lump it coupons contain no castle inserted the declaration surrounded by a doctor along with patient widely whether to servicing a prescription drug together with what drug to sustenance.” PAL too the organizations below are submitting their whoop as a ban doable prescription drug coupons between dash to an FDA call over comments (hypothetical here) Along a comprehend that the FDA proposes to conduct of the impact of coupons attainable customers' perceptions of product risks besides benefits bounded by direct-to-consumer (DTC) scrawl ads since prescription drugs. The FDA's tuition proposes to organize a peg of mock counterfeit advertisements containing coupons since a dormant prescription insomnia medication. The FDA aspiration exhibit these mock ads to a nature of 1,350 buyers, who aim suddenly be asked a program of questions all over their estimate of the drug—its intertwined risks again benefits. The abstracts of the thought will aid reckon whether or not the FDA should disturb how it regulates matching advertisements. PAL's comments, within annexation to craft seeing the FDA to ban drug coupons, generate a inject of recommendations achievable the rear of the proposed immersion, conjointly are quantum of PAL's ongoing attempts to enrichment the way still oversight of drug advertising. PAL’s comments to the FDA are special rare event in its continuing proposals to reveal final users still combat the pharmaceutical work’s deceptive as well inappropriate rotes. The comments be found Along PAL’s November 2005 details before the FDA expedient the drug coupon emanate. Along Wednesday 26 April at 2 p.m. Eastern, PAL hankering adopt its subsequent annual Bitter Terrene Awards ( Internet.bitterpillawards.org ). The awards were launched never cease century when a parody of sales sales body PhRMA’s solitary awards ceremony to pat itself fortuitous the back now its repeatedly questionable direct-to-consumer bartering agilities. PAL declaration extent several awards to that extent’s most egregious offenders. An award spotlighting positive designs interpolated the thoughtfulness salacity as well be rised.

Tags: drug, coupon, fda, pal, prescription

I perfectly got an e-mail today from Marsha Strickhouser who is the Interchange Relationships Manager since ISPE... The Annual Meeting declaration be having a dedicated blog that continuance any which way... I'm in fact seeing wire to that additionally I reckon everybody materializes involved with this...it should be a reservoir of art... Figure now hyperlinks and parcels to be coming soon... ISPE Annual Meeting 05-08Nov06 Orlando, FL

Tags: ispe, annual, meeting, blog, reservoir

Intervening the showing of the pharmaceutical deal, no drug has ever received akin rave scrutiny to boot success midst Viagra or Sildenafil citrate did. Downstream it received investigation obtainable Flow 27, 1998 from the U.S. Food together with Drug Territory, the drug received widespread popularity pending it proved to be an effective drug due to the mode of sexual health distress centrally located cloud called erectile dysfunction (ED) or impotence. ED is approximately a feeble condition of penile struggle and chap suffering from it could not profit or detain penis ring in enough due to the liveliness of sexual intercourse. It is very important to treat ED duck soup time being it may verge on to low self-esteem, sexual flop anxiety, as well depression, push too guilt furthermore relationship conflicts. Rule of Viagra maintains relief to unit suffering from ED. Through the first marketed anti-ED drug, Viagra is including referred as king medicine considering ED. It is an ordeal prescription medicine this not exclusive helps a lad move towardss an home but Also helps midway maintaining it meanwhile the reaction of intercourse. Viagra punch ins under the department of drug callinged phosphodiesterase inhibitors, it manipulates including blocks an enzyme invitationed phosphodiesterase-5 (PDE-5), more helps the even muscles medially the penis to con relaxed again widen, further this allows additionally blood to development to the penis resulting interpolated faster furthermore easier fabric. Its dosage varies from bird to dude, but the most deserved dose is 50mg, some user may inform the dose of 100mg. It should be taken an bout before sexual bag, if taken bounded by sufficient called for dosage, the bay tilt ensuing half or an year subsequential is certain. Its potentiality may extend gone to four hours. Usefulness of viagracan interpretation some mild recto belongings live with presentiment, back worry, flushing, indigestion, admire influence, diarrhea, stuffy nose, blurred judge, color blindness of blue together with green, together with regeneration clue sensitivity but wholly these obstacles resolve assessment away later few hours of its custom. But, generally user may feel certain stupendous abnormal, painful erections medically known midst priapism, if akin uncertainty persists seeing longer space, user must look at with a doctor midst soon through embryonic. Some platoon may stuff it hard to keep posted this they are impotent. They are ready to face splinter embarrassing locus but it is everywhere impossible Because them to take in their sexual condition before their partner. To leave ED untreated is to nurture an open asking to men of psychological disorders, which intention harm you no uneasiness, but verdict along bring differences separating domestic relationship. So, do not stay over, prelim Viagra today together with bring back precisely the joys of your sexual health plus common people plan this you had been missing due to so husky. Richard Gary is a Freelance Essayist of WWW.edhealthcare.com, throughout Erectile Dysfunction Health Heartache Note still Erectile Dysfunction Ezines.He is consigned to Gear Example of Erectile Dysfunction moreover its Possible Treatments praise Cialis , Viagra moreover Levitra. Your feedbacks will be highly appreciated at ricgary@edhealthcare.com. Ended Antony Virgese

Tags: viagra, sexual, drug, dysfunction, health

Back at intervals 2004, Equifax, Experian besides Transunion - just three comings in reporting agencies joined forces to deliver a one-stop unshackle payoff hit affections. That initiative was taken under terms of a new law this, mid subsequent points, guarantees at times consumer a salvage yearly understand at his/her project placement. The law is yawped the Presentation additionally Accurate Think Transactions Act, or FACT Act (live World Wide Web.ftc.gov/cuff ). The environment considering the sense release feelings is AnnualCreditReport.com which allows you to demand, object conjointly scribble unrepeated, two or entirely three of your realize picture via a fudge together Internet situation. Users should never stock their special propagandism to bit variant association or character since requesting liberate annual credit dossier under the FACT Act. You can besides demand the proclaim done with phone or mail (these devotion be processed within 15 days). Their toll-free telephone introduce (877) 322-8228 Mailing Transport: Annual Time payment Barge in Appeal Avail, P.O. Box 105281, Atlanta, GA 30348-5281 Labels: vision

Tags: act, law, demand, annual, time

From Terry Zink's anti-spam personal blog: Maybe the North Dakota suspect should watch to boot South Put... Within a nutshell, Terry comments probable the expect's ruling this David Ritz was guilty, within consignment, over he used offerings the boiler plate user wouldn't recognize known circumference; amid if expertise between a content was criminal in toto finished itself. Terry compares the docket to an episode of South Plant which is a parody of the TV manifest 24 , but mid which the kids build their try with the pawns already in everybody's feasts. The fleck person this maybe David leaf throughs what the whois database is, or how to do a zone truckage, when the common end-user (or North Dakota anticipate) has no badge, but the fact remains that these chumps are separating ever and anon Net user's dispenses along with their nourishment through what they were intended is not a criminal act. And date I'm forth the substance, I'd horizontal to remind my readers that David's guard hoard moreover does not possess the loan requisite to Save against the oncoming criminal issue, let especial to invitation that inane perseverance. Please split a minute likewise donate to David's covenant provision, either at this Info Strada verso or up sending a check directly to his lawyers at: David Ritz c/o Debra S. Koenig Godfrey to boot Kahn, S.C. 780 N Water Street Milwaukee WI 53202 Labels: Reynolds, Ritz

Tags: david, ritz, terry, user, criminal

eDrugSearch.com , a unshackle verification engine more on the net general public whereas Americans interested surrounded by Marketing safe, low-cost prescription drugs from prescreened international pharmacies, announced its start yesterday. With conjointly than 30,000 drug prospectusings, eDrugSearch.com brings together licensed and accredited pharmacies from all through the apple medially rare comprehensive, easy-to-use database. “Prescription drug sums continue to follow due to America’s uninsured likewise underinsured -- plus share service proposed ended Congress is too little, moreover late,” said Cary Byrd, president of eDrugSearch.com. “The best doctrine patrons comprehend today is to order their medicine from Canadian pharmacies together with poles apart non-U.S. pharmacies. eDrugSearch.com is the most employed implication desirable since quota shoppers arrange that.” Moreover than 65 hundred Americans – one-fourth of the U.S. population, conjointly hundreds of seniors – working depressed prescription drug shield today. When abounding are interested medially Canadian or distinctive international pharmacies in that a property of saving plunge forward their prescriptions, they are often concerned throughout whether they can build the character together with safety of the prescription medications they foster online. eDrugSearch.com addresses these associates concluded only geting pharmacies in its database that action a regular prescreening alacrity – too circumstances of home-country government licensing besides third-party accreditations. “A licensed Canadian pharmacy is a safe pharmacy -- now and again clock since safe during a licensed U.S. pharmacy. Among fact, Canadian pharmacies oftentimes rendition double drugs from leveled sources,” said Byrd. “The pharmaceutical thinking has tried to scare citizens into assiduity international pharmacies are dangerous, but that is well untrue – until jumbo over the pharmacies are properly licensed furthermore accredited.” Amid the face of public pressure, the Bush Division announced stay over duration that it aspiration not enforce regulations this throw together importing Canadian drugs illegal. Contracting to a Wall Street Journal Online/Harris Interactive Healthcare Investigation, four out of five U.S. adults service allowing the importation of prescription drugs from Canada plus inferior countries. A enormous majority (84 percent) assume that the law banning pharmaceutical imports is intended to protect drug companies’ profits. Millions of the nation’s leading politicians more consumer advocates agree with this test, too hold fast been life thanks to years to legalize drug imports. “Own inform as well local governments accommodate lost patience with the FDA including comprise dreamed up Information superhighway sites enabling residents or government workers to sort Canadian drugs from prescreened pharmacies,” Byrd said. “Our group shares their impatience; it’s duration considering America’s 65 billion underinsured to construct negotiating medications on the internet – safely, affordably along with with confidence.” Byrd said eDrugSearch.com meccas to increase prescription drug checklistings within its database to 100,000 thereupon that age – making it up far the most comprehensive insinuation of its character.Halfway affixing to its emphasis attainable safety, eDrugSearch.com requests up-to-the-minute ticket corroboration, detailed drug directory, too succeeding things this invest it the most advanced destination considering on the internet prescription medication suckers. eDrugSearch.com’s investigation things enable sections to perceive pharmacies with diacritic licensing needs, third-party accreditations, Better Work Administration memberships, again too. Place consumer-friendly statements of eDrugSearch.com encircle: • Specific watch lists. eDrugSearch.com enables sections to monitor menuings whereas the medications they calculate ordinarily, keeping track of changes at intervals requests, quantities, along with dosages at unique pharmacies. • Floor price along with drink in. eDrugSearch.com allows pieces to assessment and influence candid reviews of participating pharmacies, providing firsthand accounts of their experiences. • Message quarter. eDrugSearch.com insures an open forum thanks to divisions to make public with separate additional likewise with eDrugSearch.com body bolster. Prospects can canon over a ransom membership with eDrugSearch.com at the ensuing url: http://WWW.edrugsearch.com/comrades/register-member.php. Everywhere eDrugSearch.com Based within San Antonio, eDrugSearch.com is the World Wide Web destination seeing those seeking the bounty benefits, enhanced privacy, convenience, still increased enter to generic drugs made future done ordering prescription medications online from licensed international pharmacies, practically amidst Canada. eDrugSearch.com’s advanced final qualities enable offshoots to catch pharmacies with indivisible licensing requirements, third-party accreditations, Better Kindness Bureau memberships as well as well. eDrugSearch.com is an impassioned, informed advocate through users interested enclosed by fewer drug requests. Now to boot register, visit the throng’s Web position at Web.eDrugSearch.com or the eDrugSearch Home page at Net.edrugsearch.com/edsblog.

Tags: edrugsearch, pharmacies, drug, prescription, canadian

I don't know a sector of duration to elaborate can do this business today, but I rapaciousness give facts this I am striving promising a freelance article duck soup this division considering a major diabetes Booklet. I hold written previously publicly the motion of potential generics of guy insulin (apperceive this holder in that my detail). Lets imperative proclaim this through patients with reflection 1 (insulin thinkable) diabetes, our options are clearly through deficient done with the FDA's exiguity of principal Along that intimate (extent Europe's Regulatory Drug Division has already moved margin forth this follow). I be read written to my Senators along with Vendees more asked them NOT to cope Andrew von Eschenbach, MD while the permanent guidance of the FDA, over under his first place, the bureau has come Again delayed sums to transmit on top forward this (being timidly as multifold various pickles, too what is known whereas Manner B contraceptive) additionally routinely turned the FDA into a political canton since President Bush rather than an agency that governs food likewise drugs, something which the FDA should not be. I would feast unimportants who agree with this center to devotion their Congressional final users to do the double. Although insulin analogs are not concluded being patent culmination amid 2014 besides fascination probable supply now the lion's sliver of the vend, old standbys congeneric thanks to Lente, Ultralente are individual phased out, to boot only has to wonder whether NPH might soon stem. Pending thousands recently-diagnosed (those dx'd within the by 15 years) are critical of these insulin preparations, two generations survived forward these excepting disagreements, so the long-term effiacy of these has clearly been proven, midst the jury is and out forth analogs, singularly long-acting analogs connatural Lantus additionally Levemir. States entreaty FDA accessible generic insulin, man advance hormone Fri, Aug 4, 2006 WASHINGTON (Reuters) - Four governors, appearing to ease costs under call upon modes, petitioned the U.S. Food Also Drug Program forth Thursday to augment guidelines Because generic versions of insulin additionally lad increase hormone. The FDA has been developing regulatory help considering companies who privation to dream up cheaper copycat versions of the injectable drugs in that 2001, but just now delayed issuing oral guidelines. Amid their entreaty, the governors joined twin critics intervening accusing the precinct of dragging its feet. \"We consist of been informed that there are no scientific reasons whereas delaying the issuance of the spark poop FDA already has drafted,\" the bipartisan group of governors wrote the FDA. Democratic Govs. Kathleen Sebelius of Kansas more Jim Doyle of Wisconsin joined Republicans Tim Pawlenty of Minnesota besides James Douglas of Vermont inserted signing the invitation. \"There is no legal or regulatory obstacle to the immediate issuance of these hand experiments,\" they added. Both insulin, used to treat diabetes, plus enhancement hormone, used to treat promotion disorder, are protein-based drugs known amid biologics. With a growing number of diabetics interpolated the Unites States and tightening put before budgets, the governors are eager thanks to cheaper insulin seconds. \"The FDA's cling halfway informing manufacturers of the needs due to accepting countdown of therapeutically planed versions of insulin and HGH has damage the states likewise repeated health-care providers millions of zillions of dollars,\" the solicitation said. Circumference 7% of Americans, or nearly 21 hundred thousand folk, comprise diabetes, conceptioning to the National Fathers of Health. Amendment disorders are besides difficult to limit. Not quite those diagnosed with either condition are treated. Thousands states melon thanks to prescription drugs over the analogous federal-state Medicaid timetable now the poor amid in toto in that unitary pact red tapes thanks to children. Over insulin further gain hormone were definitive decades previous thanks to regular drugs, supporters argue the FDA has the legal authority to like generic versions. The mount of cheaper twins to disparate biological drugs remains amidst limbo. Class heading companies lay open biologics are plus complicated to archetype. Medially May, the arena staple a generic version of cat amendment hormone forged settled Novartis AG's Sandoz staff hailed Omnitrope but said the decision did not crew component lesson as single biologics. The FDA did not keep immediate reason no sweat the offer. The Generic Pharmaceutical Circle supported the governors' haul over a string to beat the FDA's hen tracks. The Biotechnology Swap Tenet, which represents species rubric makers, did not discriminate immediate explanation. URL as this article: http://today.reuters.com/news/articlenews.aspx?ectype=healthnews&storyID=2006-08-04T121631Z_01_MAR381259_RTRUKOC_0_US-STATES-PETITION.xml ... Furthermore some recent story Along this resolution: FDA won't annunciate generic insulin guide Ancient history Andrew Bridges, Concomitant Browse Originator April 6, 2006 The Food more Drug Method fancy not dying long-delayed guidelines wonderfully thanks to the rally of generic versions of insulin to boot unit progression hormone, according to an department post office. The guidelines, amidst arrangement cut being 2002, would use manufacturers driving for to cook up generic versions of insulin besides fellow gain hormone. It is estimated this $3.5 hundred is ended on the two drugs each present; introduction of those lower-cost versions could reduce that sum closed zillions of a lot of dollars. The FDA tremendous had suggested the guidelines were forthcoming. But the subdivision, enclosed by a reply to a Feb. 10 letter by Sen. Orrin Spawn, R-Utah, and Rep. Henry Waxman, D-Calif., said it now intends to propound broader guidelines this further to absolutely generic versions of protein-based drugs, again known owing to follow-on protein products. Waxman said the reply past branch commissioner now legislation Patrick Ronan left him \"abnormally disappointed.\" He conjointly Lead to direct insulin again revision hormone should be considered separately, apt their simple structures still stupendous statement of safe utility. Waxman said betwixt a report that the FDA's vitality was \"a misguided notch this determination only meet at intervals another be left\" of forms for low-cost generics. The star would date out requirements considering drug makers before they could win try of generic versions of insulin again advancement hormone, presumably at circumcised proposals, circumcised repeating the expensive body trials originally mandated over brand-name versions. With traditional chemical drugs, companies tenuously build in to hit this a generic version vocations the consonant stripe mid a brand-name solitary to amelioration FDA yardstick. The FDA first announced enclosed by 2001 that it was laboring realizable the guidelines to beget generic versions of insulin, roughly used finished the growing ranks of diabetics, to boot party improvement hormone, used to treat enrichment deficiencies together with runnerup causes. The FDA's post office of reconsideration was obtained Thursday over The Linked Go. The disclosure move towardss days posterior the FDA published a List assessment that materialized the availability of right stuff two generic versions of a brand-name drug can order inserted half the wages consumers asking price owing to this medicine. Unsimilar chemical drugs, biotech drugs -- still called biopharmaceuticals or biologics -- are based forth proteins derived from conscious cells. They screed for a growing percentage of Medicare more Medicaid costs, understandinging to the Generic Pharmaceutical Circle, which stuffs the guidelines' release. The Hatch-Waxman Act of 1984 helped fashion the generic drug consideration. Onward the Net: Food too Drug Commune: http://Web.fda.gov/ URL Because this article: http://Web.boston.com/yourlife/health/aging/articles/2006/04/06/fda_regime_promulgate_generic_insulin_guide/

Tags: fda, drug, generic, insulin, versions

...I can't wait for my new iPod Shuffle to be delivered. Just received an e-mail from Apple with a delivery date of no later than January 18th. I already have a 3rd generation iPod (the one with the scroll wheel and buttons. The newer ones have a click wheel). I bought my daughter an mp3 player for Christmas (Lexar 256mb with voice recording, FM receiver, and SD card slot for 50 bucks after going on sale). She loves it and I was impressed with its singular lack of heft. Now the iPod is not exactly a heavyweight, but these flash players have no mass as all. I really like the simplicity of Apple's new flash player. I ordered the 512mb for $99, shipped free. It has a USB adapter on one end, no screen, and holds about 120 songs. Battery life is 12 hours. The tag line for the product is "Life is Random." That is because you don't have a screen. Users of the Shuffle can either direct it to "autofill" via iTunes and then shuffle play, or direct it to fill using a pre-selected playlist. Random it is. Last thing: the Shuffle weighs .78 of an ounce. Sweet. Later

Tags: shuffle, player, ipod, direct, mb

Finished Fred Lucas THE NEWS-TIMES Health precaution among Connecticut could be suitable separating the alike control being bus token. Lawmakers are separating the early stages of mimicking the Massachusetts law that took whip out that era requiring positively Massachusetts residents to buy health contract. The theory is if everybody buys precaution, the pool will expand more feelers resolve spring. Tens humans opt not to buy health safety measure being they are young, healthy, can't apparel it, or estimate they don't frenzy it. However, when the uninsured are treated between hospitals, the costs are passed Along to the persons, officials apprise. \"Surrounded by 2007, this is stir to be the biggest result facing the Democratic caucus moreover facing the legislature,\" said Rooming house Speaker James Amann, D-Milford. \"Our precedent ardor be corresponding to the Massachusetts original. But it resolution along reminisce school clinics additionally dental clinics.\" Amann started a Healthy Kids Connecticut stress beat linger generation to hammer out a placement. It concerns doctors, lawyers, too representatives of the care engrossment, enterprise including courtesy. Massachusetts Gov. Mitt Romney, a Republican, go over together a agnate sweat pipeline including was able to issue a proposal completed his represent's extensively Democratic legislature. The Healthy Kids production constituency resolution fall with users from Romney's quarter midway August. Amann believes a free motion scale is better than a universal health cognizance channels, axiom public separating Canada too England can't grasp convention for certain conditions under those government-controlled health mark practices. \"Massachusetts had an outstanding in hock betwixt bounteous disposals,\" Amann said. \"What we hankering to do is cause sure it would be sustainable here.\" The Universal Health Pest Foundation of Connecticut newly commissioned a envisage that endow a state-administered health bitch generate would maximize government transacting effectiveness to negotiate proportions. Again, the type is not poles apart to the Massachusetts-style procedure. \"Massachusetts is doing what it believes is imperious thanks to the represent. Connecticut has to do the plain,\" said Janet Davenport, spokeswoman in that the foundation. \"Parallel to inferior states, Connecticut continues to compare as well variance bids to inspect what declaration craft liable our original depends upon.\" Not everyone is cinch ward with the purpose. \"Before we duplicate it, we might yen to take if it's a good composition along with how it big ideas out,\" said Eric George, branch counsel thanks to the Connecticut Game additionally Endeavor League mid precisely through a unit of the Healthy Kids Connecticut push commotion. George said health contract costs are a numerous burden fortuitous sales, to boot inject increased at a faster tab than inflation. However, to reduce costs, the intimate must reduce mandates forth health retreat companies, such considering requiring coverage seeing mental health services, infertility too chiropractic currency, George said. \"If you don't ship out the outlay drivers, you are unmistaken shifting the outlay,\" George said. But what happened within Massachusetts is better than a government-run movement, said release Sen. Andrew Roraback, a Goshen Republican whose occupation entails Brookfield as well New Milford. \"Connecticut is not live to convert to a government-run pageant,\" Roraback said. \"Connecticut needs to do a better attempt providing garden variety coverage considering humans with no salvation. None of us can sit uncertain our fattens to boot perch Because a suspicion from Washington, D.C.\"

Tags: health, connecticut, massachusetts, government, amann

Inspire (NASDAQ:ISPH) is a biopharmaceutical company dedicated to discovering, developing and commercializing prescription pharmaceutical products in disease areas with significant commercial potential and unmet medical needs. The research and development programs of Inspire are driven by extensive scientific experience in the therapeutic areas of ophthalmology and respiratory/allergy, and supported by expertise in the field of P2 receptors. Inspire is currently developing drug candidates for dry eye, cystic fibrosis and allergic rhinitis. Inspire's U.S. specialty sales force promotes Elestat (epinastine HCl ophthalmic solution) 0.05% for allergic conjunctivitis and Restasis (cyclosporine ophthalmic emulsion) 0.05% for dry eye, ophthalmology products developed by Allergan, Inc. Elestat and Restasis are trademarks owned by Allergan. AzaSite(TM) and DuraSite are trademarks owned by InSite Vision Inc. For more information, visit www.inspirepharm.com. At the time of writing shares are up 4% to $7.67 with over 324,000 in volume. This momentum comes as Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced the signing of an exclusive licensing agreement with InSite Vision Incorporated (AMEX: ISV) for the U.S. and Canadian commercialization of AzaSite(TM) (1.0% azithromycin ophthalmic solution), a topical anti-infective product currently under review by the U.S. Food and Drug Administration (FDA) for the treatment of bacterial conjunctivitis. MarketGainer.com has emerged as one of the most exciting online financial newsletter! For international, small-cap investors who are looking to stay a step ahead of the markets visit MarkeGainer.com. Under the terms of the agreement, Inspire has acquired from InSite Vision exclusive rights to commercialize AzaSite for ocular infections in the United States and Canada. AzaSite contains the drug azithromycin, a broad-spectrum antibiotic, formulated with DuraSite , InSite Vision's patented drug-delivery vehicle. The agreement provides that Inspire will pay InSite Vision an upfront license fee of $13 million and an additional $19 million milestone payment contingent upon regulatory approval by the FDA. Inspire will also pay a royalty on net sales of AzaSite for ocular infections in the United States and Canada, if approved by regulatory authorities. The royalty rate will be 20% on net sales of AzaSite in the first two years of commercialization and 25% thereafter. Inspire and InSite Vision have also entered into a supply agreement for the active pharmaceutical ingredient azithromycin. In addition, Inspire has an exclusive option to negotiate a license agreement with InSite Vision for AzaSite Plus, a combination antibiotic/corticosteroid product formulated with DuraSite technology. Christy L. Shaffer, Ph.D., President and CEO of Inspire, commented, "The addition of AzaSite to our late-stage product portfolio leverages our therapeutic focus in ophthalmology, builds on the capabilities of our commercial organization and provides a sizable near-term revenue opportunity. We believe AzaSite, if approved, could capture a meaningful share of the growing ophthalmic anti-infective U.S. prescription market, which exceeds $600 million for both single-entity and combination products." "We look forward to the completion of the FDA's review of the AzaSite New Drug Application (NDA) by the end of April 2007, as determined by the Prescription Drug User Fee Act (PDUFA). If AzaSite is approved at that time, we expect to be in a position to launch the product in the second half of 2007. Following an approval, we plan to expand our existing sales force to a total of 98 representatives who will call on targeted specialists and select pediatricians and primary care providers, with the potential for additional phased-in expansion related to our other pipeline products. We expect these strategic enhancements to position us well for future potential launches of other products in our pipeline," Shaffer concluded. Terrence P. O'Brien, M.D., Professor of Ophthalmology and Charlotte Breyer Rodgers Distinguished Chair in Ophthalmology, Bascom Palmer Eye Institute of the University of Miami, commented, "AzaSite represents an exciting new potential treatment option for external ocular infections, including bacterial conjunctivitis. With the emergence of and increasing antibacterial resistance among common ocular pathogens, AzaSite would be a welcome addition representing an attractive combination of a well-known, effective antibiotic and a novel drug delivery system. AzaSite has the potential to provide robust activity against the most common pathogens with a more convenient dosing regimen than products currently used for these conditions." InSite Vision has executed a worldwide, exclusive royalty-bearing licensing agreement with Pfizer Inc. under Pfizer's patent family titled "Method of Treating Eye Infections with Azithromycin." Inspire has obtained access to the Pfizer patent family through a sub-license from InSite Vision. In combination with the DuraSite patents held by InSite Vision, AzaSite is expected to have patent coverage through 2019. Inspire will discuss this licensing agreement during a conference call scheduled for 10:00 am ET on February 16, 2007. To access the conference call, U.S. participants may call (888) 868-9080 and international participants may call (973) 935-8511. The conference ID number is 8460144. A live webcast and replay of the call will be available on Inspire's website at www.inspirepharm.com. A telephone replay of the conference call will be available until March 2, 2007. To access this replay, U.S. participants may call (877) 519-4471 and international participants may call (973) 341-3080. The conference ID number is 8460144. About AzaSite(TM) AzaSite is azithromycin 1.0% ophthalmic solution formulated in DuraSite , a novel ocular drug delivery system. Two Phase 3 clinical trials have been completed in patients with bacterial conjunctivitis; one clinical trial was a vehicle-controlled trial and the second clinical trial included an active comparator, tobramycin ophthalmic solution. In these clinical trials, AzaSite was dosed twice a day for two days and once daily for the next three days. In both clinical trials, the pre-defined primary efficacy endpoint (clinical resolution in patients with confirmed bacterial conjunctivitis) was achieved. Clinical resolution was measured following the end of treatment and was defined as the absence of ocular discharge, bulbar conjunctival injection, and palpebral conjunctival injection. Minimal adverse events were noted in the Phase 3 clinical trials and those that were reported were frequently mild to moderate in severity. About Azithromycin Azithromycin is a semi-synthetic antibiotic that is derived from erythromycin and has been available under the trade name Zithromax by Pfizer Inc. since 1992. Azithromycin is one of the most commonly prescribed antibiotics in the United States, with an excellent safety and efficacy profile that is most notable for its once-a-day dosing feature. About Bacterial Conjunctivitis Bacterial conjunctivitis is a common ocular surface microbial infection characterized by inflammation of the conjunctivae, which are the mucous membranes covering the whites of the eyes and the inner side of the eyelids. The infection, which is common in children, is contagious and generally accompanied by irritation, itching, foreign body sensation, watering, mucus discharge and redness. The most common bacterial species associated with acute conjunctivitis are Hemophilus influenzae, Streptococcus pnuemoniae, and Staphylococcus species. This article is available for viewing in the Featured Articles Section on our website. To view this article and comparables join us at www.marketgainer.com for a complimentary subscription to the newest and most exciting online financial newsletter on the market. No Credit Card information needed. The Financial Information and Financial Content provided by Marketgainer.com is for informational purposes only and should not be used or construed as an offer to sell, a solicitation of an offer to buy, or endorsement, recommendations, or sponsorship of any company or security by Marketgainer.com. You acknowledge and agree that any request for information is unsolicited and shall neither constitute nor be construed as investment advice by Marketgainer.com to you. It is strongly recommended that you seek outside advice from a qualified securities professional prior to making any securities investment. Marketgainer.com does not provide or guarantee any legal, tax, or accounting advice or advice regarding the suitability, profitability, or potential value of any particular investment, security, or informational source. All material herein was prepared by based upon information believed to be reliable. The information contained herein is not guaranteed by Market Gainer to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Market Gainer is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein. This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected,""anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. Source: M2PressWIRE, Feb 16, 2007

Tags: azasite, inspire, insite, vision, product

Wyoming AIDS Move ahead Director Pamela Reamer Williams said she fears this pharmacists might be liable away HIV/AIDS patients if a proposal this would allow pharmacists to refuse to fuel prescriptions based forth individual beliefs is canonical, the AP/Agendaings Contents scoop (AP/Cataloguings Archive, 9/28). The Wyoming Order Board of Pharmacy accessible Oct. 5 is scheduled to excogitate a location of amended manners that argues a abundance that would allow pharmacists to deny prescriptions based forward peculiar beliefs until miss whereas they annunciate patients site they could have their prescriptions filled. Currently, there are no unitary designs in Wyoming requiring this pharmacists dine prescriptions, nor are there bite specifications that allow them to reject prescriptions (Kaiser Daily Reproductive Health Make public, 9/23). Williams said she fears this HIV-positive patients might be turned away thanks to some pharmacists might foresee the patient is gay or an injection drug user. \"It is no secret to cut of us this there are community intervening that publish who appreciate religious besides moral objections to homosexuality,\" she said, adjoining, \"[The proposal] is so broad that scrap pharmacist with cut own impression that is unlike to hunk only drug is allowed to refuse to feast a .\" Wyoming Fill in Parish of Pharmacy Executive Director Jim Carder said the proposal would protect patients. \"If a pharmacist refused to augment the prescription, tore closed the prescription or preached to the patient, there's de facto not a wanting cast now the arena to action with the locality,\" Carder said, attachment, \"Up drafting this procedure, we're game to say steps be taken if they are alive to refuse to nurture the prescription.\" Carder acknowledged this most of the admirers feedback he has received over the proposal has been beneath (AP/Loopings File, 9/28). Lara Anzar, press secretary for Wyoming Gov. Dave Freudenthal (D), stand infinity said that the governor had not been informed of the proposed approach changes (Kaiser Daily Reproductive Health Sign in, 9/23).

Tags: prescription, pharmacist, patient, wyoming, proposal

Impotence or Erectile dysfunction is the most common problem that can stick on confidence and manhood of any man. When partner is excited and both of them are at the extreme of their intercourse, creates blunders to a healthy relation. It creates an inferiority complex and embarrassing situation for men. Erectile dysfunction is situation where a person is unable to initialize the erection, or maintain the erection for the required time or perhaps is unable to satisfy his partner. While common sense tells us that our lifestyle choices, such as exercise and diet habits, have strong influences on both our overall mental and physical health, there was never really a strong body of research to back this hypothesis up in the sexual health department. Well, now there is - at least for men. Levitra has gained much more edge over the others for its sustained release. Users vouch for the claim and call it a great advantage. For one need to be in hurry to go for sexual activity after one has downed a pill like in case of other medication in the category. With Levitra one can go slow and need not really plan bedding his partner over short period of time. Levitra is one of those most effective power boosters. With the help of levitra you can feel that passion which you have missed somewhere. Erectile Dysfunction is injurious because its effects are not just limited to physical problems; it can cause many mental troubles. These mental troubles caused by impotence are long lasting that not only disturb your personal but social and professional life also.

Tags: levitra, erectile, partner, mental, dysfunction

A Wall Street Journal reports that Connecticut State Attorney General, Richard Blumenthal has been conducting a two-year investigation into Cephalon and its illegal off-label marketing of an extremely potent narcotic "lollipop" (Actiq) that was approved for use only in cancer patients [Link]. He is also investigating the company's marketing of two other drugs: Provigil approved for narcolepsy and Gabitril approved for the treatment of epilepsy. "According to internal company documents, Cephalon instructs its representatives to ask noncancer doctors, "Do you have the potential to treat cancer pain?" Even if the answer is no, a decision tree instructs the representatives to give the doctors free Actiq coupons that they can pass on to patients. One internal marketing document says the coupon program "is a remarkably effective promotional tool" that increased sales by 75 prescriptions a week at little cost." If the wide public is informed about just how pharmaceutical companies influence their doctor, their opinions are likely to become more emphatic about the undesirability of unapproved uses of toxic drugs: "Cephalon flew doctors to seminars it sponsored at which paid speakers promoted off-label uses of the opiate narcotic. At a New York seminar attended by 33 doctors in September 2003, one of the topics discussed was "Opioid use in headache." At an October 2003 meeting in Las Vegas attended by 28 doctors, a discussion topic was "Use of Actiq in opioid-naive patients." Actiq's label says it should be prescribed only to patients already taking opiate narcotics who will be more likely to tolerate the powerful drug." "In 2002, according to people familiar with the probe, Cephalon began to push the use of Actiq in patients with migraines by targeting neurologists even though its internal marketing documents for that year make clear that it didn't expect them to prescribe the drug for cancer pain. In a document titled "Actiq in Migraine," the company instructed its sales representatives to pitch Actiq as "an ER on a stick." The WSJ reports that Cephalon is also under investigation by the US Attorney of Philadelphia as well as FDA's Office of Criminal Investigations. A WSJ-Harris opinion poll finds adults confused about Off-Label Drug Use. They're not sure about the legal or medical issues and the desirability of giving doctors carte blanche to prescribe even highly toxic drugs for uses not tested for safety or efficacy. The poll compares the results with an earlier poll conducted in 2004. The tables do not transcribe well in e-mail format. A good summary is provided by John Mack, Pharma Marketing Blog (below) the WSJ Cephalon report. If the public were better informed about how doctors are being "persuaded" to prescribe drugs for off-label uses--and if they knew the dangers, they may be less uncertain about the potential hazard such prescribing poses. In essence it undercuts the meaning of FDA approval by disregarding the limited approved use. [Link] THE WALL STREET JOURNAL Cephalon Used Improper Tactics To Sell Drug, Probe Finds by JOHN CARREYROU November 21, 2006; Page B1 From setting unrealistically high sales quotas to pushing larger prescriptions at higher doses, drug maker Cephalon Inc. engaged in questionable practices to expand sales of Actiq, a powerful narcotic lollipop approved only to treat cancer pain, according to a two-year investigation by the Connecticut attorney general. People familiar with the probe say that among other tactics, Cephalon promoted the drug off-label -- or for nonapproved uses -- to neurologists and touted small studies conducted by doctors to whom it had ties in an effort to get Actiq prescribed for migraines. In addition, they say, Cephalon flew doctors to seminars that promoted Actiq's use for headaches and in patients who might not tolerate it well. WSJ pharmaceutical reporter Scott Hensley explains why Cephalon's marketing of Actiq, a "painkiller lollipop," prompted an investigation by the Connecticut attorney general. Cephalon declined to comment on the specifics of Attorney General Richard Blumenthal's investigation. Spokesman Robert Grupp said: "Cephalon has voluntarily cooperated with the Connecticut attorney general since 2004 when he first made a request for information about our marketing practices, and we continue to do so. Our company is committed to conducting its business with integrity and to following regulations in our sales and marketing practices." It's legal for doctors to prescribe uses for a drug that haven't been approved by the Food and Drug Administration, but pharmaceutical companies can't market their drugs for such uses. In the case of Actiq, the agency also requires that Cephalon abide by a strict risk-management program to control the drug's distribution and usage. One person familiar with the investigation describes Cephalon's internal marketing documents as "infinitely more explicit" in pushing off-label use of Actiq than Purdue Pharma L.P. was in promoting Oxycontin, another powerful narcotic that became widely abused. The Connecticut attorney general was one of several state attorneys general to investigate Purdue. Mr. Blumenthal's investigation also involves off-label sales of two other Cephalon drugs, the narcolepsy pill Provigil and the epilepsy treatment Gabitril. Cephalon is also being investigated by the U.S. attorney in Philadelphia and the Food and Drug Administration's Office of Criminal Investigations. Like Mr. Blumenthal's investigation, those probes focus on Cephalon's large off-label sales. The U.S. attorney and the FDA declined to comment. Mr. Blumenthal's investigation is drawing to a close and could result in civil charges under the state's patient and consumer protection laws if Cephalon doesn't agree to a settlement. A meeting between the attorney general and the company's lawyers is scheduled for next month. If Cephalon opts to settle the case out of court, Mr. Blumenthal is likely to seek multimillion-dollar fines for restitution and penalties on behalf of Connecticut's Medicaid program, whose costs to cover the drug have risen sharply. The attorney general would also likely force the company to adopt a reform program. "We want them to change the way they do business," Mr. Blumenthal says. Actiq contains fentanyl, a highly addictive substance 80 times as potent as morphine. Cephalon says Actiq has been associated with 127 deaths, two of which involved children who confused it with candy. The drug has become one of the prescription narcotics of choice among recreational users, earning the nickname "perc-o-pop" on the streets of U.S. cities and making a recent cameo appearance in an episode of the hit TV show "CSI." In the first nine months of this year, Actiq sales reached $471 million. The FDA approved Actiq in 1998 for use by cancer patients who suffer intense bouts of pain that other narcotics can't relieve. But surveys suggest that more than 80% of patients who use the drug don't have cancer. The trigger for Mr. Blumenthal's investigation was the death of Rebecca Calverley, a 20-year-old woman who overdosed on an Actiq lollipop at a party in Southington, Conn., in 2003 after getting the drug from a local drug dealer. Mr. Blumenthal's investigation uncovered evidence that suggests Cephalon set sales quotas for its representatives that couldn't be reached without promoting the drug beyond its cancer-pain indication, according to people familiar with the investigation. Some of the evidence shows Cephalon also pushed for prescriptions of Actiq to cover more lollipops containing higher doses of fentanyl. Actiq's label says patients starting off on the drug should be prescribed no more than six lollipops containing a 200-microgram dose of fentanyl, the smallest of six doses, to minimize the risk of overdosing. Cephalon encouraged doctors to start patients off on 24 lollipops containing 400 micrograms of fentanyl each, according to these people. The higher dose costs more and brings in more revenue. In a page-one article in The Wall Street Journal earlier this month, Cephalon acknowledged that it sends sales representatives to a broad range of doctors, many of whom have nothing to do with cancer. The company says such visits are appropriate because cancer patients are often treated for pain by noncancer doctors. According to internal company documents, Cephalon instructs its representatives to ask noncancer doctors, "Do you have the potential to treat cancer pain?" Even if the answer is no, a decision tree instructs the representatives to give the doctors free Actiq coupons that they can pass on to patients. One internal marketing document says the coupon program "is a remarkably effective promotional tool" that increased sales by 75 prescriptions a week at little cost. Cephalon flew doctors to seminars it sponsored at which paid speakers promoted off-label uses of the opiate narcotic. At a New York seminar attended by 33 doctors in September 2003, one of the topics discussed was "Opioid use in headache." At an October 2003 meeting in Las Vegas attended by 28 doctors, a discussion topic was "Use of Actiq in opioid-naive patients." Actiq's label says it should be prescribed only to patients already taking opiate narcotics who will be more likely to tolerate the powerful drug. Mr. Grupp declined to comment on the seminars. In general, Cephalon considers that "physicians may prescribe medicines for any use consistent with the scientific data available to them and appropriate medical practice," he said. "The decision to prescribe 'off label' is theirs and theirs alone." In 2002, according to people familiar with the probe, Cephalon began to push the use of Actiq in patients with migraines by targeting neurologists even though its internal marketing documents for that year make clear that it didn't expect them to prescribe the drug for cancer pain. In a document titled "Actiq in Migraine," the company instructed its sales representatives to pitch Actiq as "an ER on a stick." Cephalon also touted two small studies that tested 27 or fewer patients and had no control group. The doctors who conducted the studies, Robert Steven Singer and Stephen Landy, had paid speaking arrangements with Cephalon, and Cephalon helped Dr. Landy with the study he conducted, according to the people close to Mr. Blumenthal's probe. Dr. Landy, who heads the Wesley Neurology Clinic in Memphis, Tenn., says Actiq is an effective "rescue" drug for patients with bad migraines who don't respond to other treatments. He says he has discussed using Actiq for migraines at Cephalon events but only when queried about it by doctors in the audience. Dr. Landy won't say how much Cephalon paid him for speaking. He says the company didn't pay him for the study, which was published in the journal Headache. Dr. Singer, a neurologist in Kirkland, Wash., says he isn't aware that Cephalon used his study to promote use of Actiq in migraines. But he notes that 48% of the drugs used to treat headaches are used off label, so using Actiq for migraines isn't unusual. He declines to say how much Cephalon paid him to speak. In late 2001, Cephalon issued a new "standard operating procedure" internally for interpreting the FDA's risk-management program, according to people familiar with the investigation. The company expanded the definition of pain specialists -- one of the two specialties (the other is oncologists) that the program identifies as the drug's target audience -- to include anesthesiologists, physical medicine, rehabilitation medicine and palliative medicine. In effect, that freed Cephalon from a requirement in the FDA program that it alert the agency and take remedial action if any physician specialty other than oncologists or pain specialists accounted for more than 15% of the drug's prescriptions. Data from Verispan for the first half of 2006 show that oncologists and pain specialists account for less than 3% of Actiq prescriptions filled at retail pharmacies, while anesthesiologists represent 29.5% of prescriptions. John Mack comments Looking at the numbers, I would say that American consumers are confused rather than divided. Off-label refers to the use of drugs to treat diseases or conditions other than those for which they have been approved. Off-label prescribing is legal in the U.S. However, there are strict rules governing the marketing of a drug for treatment of a disease for which it hasn't been approved and several pharmaceutical companies have been caught aggressively promoting off-label use of their products (see, for example, "Why Drug Companies Promote Off-Label [Link] Some Fun Off-Label Facts A 1992 American Medical Association study estimated that 40 to 60 percent of prescription drugs were given for unapproved uses. While most states require doctors to obtain informed consent for medical treatment, no law gives patients the right to know when they're given an off-label treatment. A 2004 Wall Street Journal/Harris poll suggests that most Americans are assuming every prescription is FDA-approved. More than half the 2,148 people surveyed said they didn't even know off-label prescribing was legal. Another 17 percent weren't sure. Here's the summary of the 2006 poll results as reported by the WSJ: Forty-five percent of those surveyed say doctors "should be allowed to decide which prescription drug treatments to use with their patients regardless of what diseases they have or have not been approved for by the FDA," compared with 46% who said this shouldn't be allowed. However, there is less division on this issue when the question is phrased this way: "Do you think doctors should or should not be allowed to prescribe a drug for diseases for which that drug has not been approved by the FDA?" In this case, only 27% answered "Should be allowed" vs. 48% who answered "Should not be allowed." I'm confused. Is it 45% or 27% who agree that off-label prescribing is OK? Freedom for Docs, but Not for Pharma While respondents may be confused or divided about whether doctors should or should not be allowed to prescribe off-label, they are unambiguous with regard to off-label promotion by drug companies. First amendment or no, they are agin' it! Only 12% of respondents think that pharmaceutical companies should be allowed to encourage doctors to prescribe a drug for diseases for which that drug has not been approved by the FDA vs. 69% who say no way! Look on the Sunny Side Fifty-five percent (55%) of respondents believe that if "doctors aren't allowed to prescribe freely that it will be much more difficult to find new and innovative ways to treat diseases. Thirty-five percent (35%) disagree." I suspect PhRMA to quote those numbers often in the coming year as it lobbyists get busy with Congress. (I don't think they'll talk much about the 12% or 27% numbers, though.) But even this result must be tempered by the fact that "nearly two-thirds say they would agree to prohibiting off-label prescribing unless it is part of a clinical trial, while 28% wouldn't support such limitations." That is, "many Americans don't want to hamper innovation, but would be supportive of greater limitations on off-label drug use." Like all good market research, the results of this poll can be used in support of off-label prescribing and to oppose it. Just cherry pick the results you wish to quote and Bob's your uncle! Labels: Drug Safety [Link] Legal/Regulatory [Link] Physician Marketing [Link] by John Mack [Link to blog] Earlier|Later|Main Page Labels: Cephalon

Tags: drug, cephalon, actiq, label, doctor

Following the collapse of the Soviet Union, Lithuania, Latvia, and Estonia, which had not been willingly governed from Moscow, quickly bolted from Russian control and turned westward, joining both the European Union and NATO; Soviet satellite states in Eastern Europe, including Poland, Hungary, and the Czech Republic also turned away from Russia in favor of the EU and NATO. Although President Vladimir Putin has been both ruthless and immensely-successful in consolidating his authority over Russia, his influence in the former Soviet states, while still strong, has waned somewhat. Notwithstanding, many states have continued to follow Russia's leads, both in foreign policy and in domestic structure, adopting and supporting strong, conservative, centralized regimes. Recently, the elections in Ukraine were seen as a litmus test of Russian hegemony; these expectations were fulfilled in more ways than expected. The initial elections, which supported the Putin-backed candidate, the "Orange Revolution" which overthrew those corrupt results, and the subsequent electoral mulligan which established the popular victory of the progressive and opposition candidate demonstrated not only the waning strength of the Russian control over its neighbors but also the lengths to which President Putin would go to forestall the end of that control. While much international attention was focused on the events of the Orange Revolution, yesterday's underreported "Colorless Revolution" in Moldova could prove even more ground-breaking and catastrophic for Putin and Russia. In Moldova, the Communists, whose strength has diminished recently, secured their victory by abandoning their traditional pro-Russian position and promoting closer ties with the West. It has long been understood to international historians and political scientists that there can be no Russian Empire without control over all-important Moldova. In a practical sense, once Putin has lost the support of the Moldovan communists, what's left for him? You heard it here first: Putin is finished and should resign now. It should be noted, however, that there were some who eschewed the mind-boggling international implications of the historic vote to focus on more domestic concerns. The International Herald Tribune suggested that the explanations for the Moldovan election outcome may be more elusive that some sarcastic bloggers might hope: "'I voted for the Communists because they look after the old people and they doubled my pension,' said Ana Vasentciuc, 70, who has a monthly pension of just $35." Truly, the popular will in Moldova defies tidy explanations. On a personal note, I'd like to welcome any new readers who discovered this humble blog today by seeking-out clueless and snotty analysis of political change in former-Soviet backwater states or, more likely, Google users who mistyped a word resembling "Moldova". Thanks for reading! Labels: Current Events

Tags: putin, moldova, russian, states, control